Human MD-1 homologue is a BCG-regulated gene product in monocytes: Its identification by differential display

Biochemical and Biophysical Research Communications

Volumn 256, Issue 2, 1999, Pages 325-329

  Begum, Nasim A ^a   Tsuji, Shoutaro ^a,c   Nomura, Midori ^a,c   Shida, Kyoko ^a   Azuma, Ichiro ^b   Hayashi, Akira ^a,c   Matsumoto, Misako ^a,c   Seya, Tsukasa ^a,c   Toyoshima, Kumao ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Organization for Pharmaceutical Safety and Research OPSR   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GENE PRODUCT;

ARTICLE; B LYMPHOCYTE; CHICKEN; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

GALLUS GALLUS; MURINAE; MYCOBACTERIUM BOVIS BCG;

EID: 0033574167     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.1999.0329     Document Type: Article

References (22)

1. Ribi E., Azuma I., Meyer T., Parker R., Brehmer W., Yamamura Y. Chemical structure and biological functions of mycobacterial cell walls with special reference to immunity against airborne infection withM. tuberculosis. Bull. Intern. Union Against Tuberculosis. 49:1975;340-350.
2. Azuma I., Ribi E. E., Meyer T. J., Zbar B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Natl. Cancer Inst. 52:1974;95-101.
3. Yamamura Y., Azuma I., Taniyama T., Sugimura K., Hirano F., Tokuzen R., Okabe M., Nakahara W., Yasumoto K., Ohta M. Immunotherapy of cancer with cell wall skeleton ofMycobacterium bovis. Ann. N. Y. Acad. Sci. 277:1976;209-227.
4. Knutson K. L., Hmama Z., Herrera-Velit P., Rochford R., Reiner N. E. Lipoarabinomannan ofMycobacterium tuberculosis. J. Biol. Chem. 273:1998;645-652.
5. Zbar B., Ribi E. E., Meyer T. J., Azuma I., Rapp H. J. Immunotherapy of cancer: Regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J. Natl. Cancer Inst. 52:1974;1571-1577.
6. Yoshimoto T., Azuma I., Nishikawa H., Sakatani M., Ogura T., Hirano F., Yamamura Y. Experimental immunotherapy of neoplastic pleural effusion with oil-attached BCG cell-wall skeleton in mice. Jpn. J. Cancer Res. 67:1976;737-740.
7. Hayashi A., Doi O., Azuma I., Toyoshima K. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc. Jpn. Acad. 74:1998;50-55.
8. Hayashi A. Interferon-gamma as a marker for the effective cancer immnotherapy with BCG-Cell wall skeleton. Proc. Jpn. Acad. 70:1994;205-209.
9. Seya T., Begum N. A., Nomura M., Tsuji S., Matsumoto M., Toyoshima K. Innate immune therapy for cancer: Seeking for effective molecules for activation of the innate immune system. Human Gene Therapy. 1999;Plenum.
10. Miyake K., Shimazu R., Kondo J., Niki T., Akashi S., Ogata H., Yamashita Y., Miura Y., Kimoto M. Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J. Immunol. 161:1998;1348-1353.
11. Seya T., Ballard L., Bora N., Kumar V., Cui W., Atkinson J. P. Distribution of membrane cofactor protein (MCP) of complement in human peripheral blood cells. Eur. J. Immunol. 18:1988;1289-1294.
12. Begum N. A., Mori M., Matsumata T., Takenaka K., Sugimachi K., Barnard G. F. Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology. 22:1995;1447-1455.
13. Buess M., Moroni C., Hirsch H. H. Direct identification of differentially expressed genes by cycle sequencing and cycle labelling using the differential display PCR primers. Nucleic Acids Res. 25:1997;2233-2235.
14. Burk O., Klempnauer K. H. Estrogen-dependent alterations in differentiation state of myeloid cells caused by a v-myb / estrogen receptor fusion protein. EMBO J. 10:1991;3713-3719.
15. Yamashita Y., Miyake K., Miura Y., Kaneko Y., Yagiya H., Suda T., Nagata S., Nomura J., Sakaguchi N., Kimoto M. Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: A role for Fc receptor coligation. J. Exp. Med. 184:1996;113-120.
16. Medzhitov R., Janeway C. A. Innate immunity: The virtues of a nonclonal system of recognition. Cell. 91:1997;295-298.
17. Gerard C. For whom the bell tolls. Nature. 395:1998;217-219.
18. Miura Y., Shimazu R., Miyake K., Akashi S., Ogata H., Yamashita Y., Narisawa Y., Kimoto M. RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood. 92:1998;2815-2822.
19. Janeway C. A., Travers P. The recognition of antigen. Immunobiology. 1997;Garland Publishing Inc. New York.
20. Bonnert T. P., Garka K. E., Parnet P., Sonoda G., Testa J. R., Sims J. E. The cloning and characterization of human MyD88: A member of an IL-1 receptor related family. FEBS Lett. 402:1997;81-84.
21. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9:1998;143-150.
22. Muzio M., Natoli G., Saccani S., Levrero M., Mantovani A. The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 187:1998;2097-2101.